구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cell therapy with bispecific antibodies (Cell therapy with bispecific antibodies) Janssen Research & Development, LL…·Gynecological Solid Tumors 32 trials |
|---|---|
Overview Program | Cell therapy with bispecific antibodies |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | CGT |
Overview Target | Gynecological Solid Tumors |
Overview Indication | Gynecological Solid Tumors |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer.. Amivantamab, a bispecific antibody targeting epidermal growth factor and mesenchymal-epithelial transition receptors, was initially approved under accelerated approval as a monotherapy for second-line treatment of non-small cell lung cancer (NSCLC) wit… |
Toxicology CRS | Reported |
Clinical Safety signal | Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer.. Amivantamab, a bispecific antibody targeting epidermal growth factor and mesenchymal-epithelial transition receptors, was initially approved under accelerated approval as a monotherapy for second-line treatment of non-small cell lung cancer (NSCLC) wit… |
Clinical Program phase | PRECLINICAL |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cell therapy with bispecific antibodies (Cell therapy with bispecific antibodies) Janssen Research & Development, LL…·Gynecological Solid Tumors 32 trials |
|---|---|
Overview Program | Cell therapy with bispecific antibodies |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | CGT |
Overview Target | Gynecological Solid Tumors |
Overview Indication | Gynecological Solid Tumors |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer.. Amivantamab, a bispecific antibody targeting epidermal growth factor and mesenchymal-epithelial transition receptors, was initially approved under accelerated approval as a monotherapy for second-line treatment of non-small cell lung cancer (NSCLC) wit… |
Toxicology CRS | Reported |
Clinical Safety signal | Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer.. Amivantamab, a bispecific antibody targeting epidermal growth factor and mesenchymal-epithelial transition receptors, was initially approved under accelerated approval as a monotherapy for second-line treatment of non-small cell lung cancer (NSCLC) wit… |
Clinical Program phase | PRECLINICAL |
추천 비교
추천 비교